Skip to content
Screener

Climb Bio, Inc. CLYM GB — Net Income Loss

Other geography segments

US
-$59.58M+11.3%

Similar metrics at other companies

AMC Robotics Corporation logo
AMCIEurope — Net Income Loss
$238+101%
International Tower Hill Mines logo
THMCA — Net Income Loss
$2.88M+1,240%
International Tower Hill Mines logo
THMUS — Net Income Loss
-$610.01K-46.6%
FTE
FTEKCN — Net Income Loss
-$13K+27.8%
NewAmsterdam Pharma Company logo
NAMSNet Income Loss
-$64.14M-269%
Orthofix Medical Inc. logo
OFIXNet Income Loss
-$15.8M-12.2%

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$804.11M+621%
Enterprise value$796.23M+790%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Climb Bio, Inc.’s 10-K, filed March 5, 2026.

Filed
Mar 5, 2026, 7:20 AM EST
Fiscal year
FY2025
Accession
0001193125-26-092546
Line itemYear Ended December 31, 2025Year Ended December 31, 2024
Interest income8,3238,132
Foreign currency loss(291)(9)
Total other income, net8,0328,123
Net loss$(59,851)$(73,897)
Net loss per share, basic and diluted$(0.88)$(1.53)
Weighted-average common shares outstanding, basic and diluted67,812,14548,163,301
Comprehensive loss:
Net loss$(59,851)$(73,897)

Item 8. Financial Statements and Supplementary Data.

FAQ

What is Climb Bio, Inc.'s GB — net income loss?
Climb Bio, Inc. (CLYM) reported GB — net income loss of -$68K in Q4 2025.
How has Climb Bio, Inc.'s GB — net income loss changed year-over-year?
Climb Bio, Inc.'s GB — net income loss increased by 96.0% year-over-year, from -$1.69M to -$68K.
What is the long-term trend for Climb Bio, Inc.'s GB — net income loss?
Over 4 years (2021 to 2025), Climb Bio, Inc.'s GB — net income loss has grown at a -70.1% compound annual growth rate (CAGR), from -$34.17M to -$272K.
What does GB — net income loss mean?
This metric represents the net profit or loss generated by the specific business segment or geographic region after accounting for all allocated operating expenses and costs. It serves as a key indicator of the segment's financial viability and its contribution to the overall bottom line of the organization. Monitoring this figure helps stakeholders evaluate the operational efficiency and profitability trends of the segment over time.

Ask your AI about Climb Bio, Inc.'s gb — net income loss.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude